Education and Training
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to standard of care regimens in participants with relapsed or refractory multiple myeloma (RRMM).
Stanford is currently not accepting patients for this trial.
Intervention(s):
- drug: Alnuctamab
- drug: Pomalidomide
- drug: Daratumumab
- drug: Elotuzumab
- drug: Carfilzomib
- drug: Dexamethasone
Eligibility
Inclusion Criteria
- Participant is willing and able to adhere to the study visit schedule and other
protocol requirements including bone marrow aspirations and/or biopsies and
hospitalization during the first cycle.
- Documented diagnosis of multiple myeloma (MM), and must:.
i) Received at least 1 but not more than 3 prior lines of anti-myeloma therapy.
ii) Received prior treatment with lenalidomide and an anti-CD38 monoclonal antibody (for at
least 2 consecutive cycles).
iii) Achieved minimal response (MR) or better to at least 1 prior anti-myeloma therapy.
iv) Documented PD during or after their last anti-myeloma therapy or failure to achieve
response.
- Must have measurable disease (as determined by central laboratory).
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2 at the
time of the screening.
Exclusion Criteria
- Active, uncontrolled, or suspected infection.
- Known current, or history of, central nervous system involvement of multiple myeloma.
- History or presence of clinically relevant CNS pathology.
- Received prior BCMA-targeted TCE or BCMA-targeted CAR-T therapy.
- Previously received allogeneic stem cell transplantation at any time or received
autologous stem cell transplantation within 3 months of initiating study intervention.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kelly Chyan
650-625-8130
Not Recruiting